The Swiss pharmaceutical company is exercising its option to acquire the global rights to U.S.-based Sironax’s delivery platform, designed to help therapeutics cross the blood–brain barrier. Sironax will receive 125 million dollars for the deal, while retaining the rights to develop and commercialize a number of selected drug candidates using the platform.
Novartis expands brain‑delivery push with Sironax deal
Novartis continues to invest in new methods for the efficient delivery of medicines to the brain.
Advertisement
BREAKING